These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1329748)

  • 41. Advantage of combined treatment of CPT-11 and 5-fluorouracil.
    Matsuoka H; Yano K; Takiguchi S; Kono A; Seo Y; Saito T; Tomoda H
    Anticancer Res; 1995; 15(4):1447-52. PubMed ID: 7654033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
    Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
    Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
    Kubota N; Kanzawa F; Nishio K; Takeda Y; Ohmori T; Fujiwara Y; Terashima Y; Saijo N
    Biochem Biophys Res Commun; 1992 Oct; 188(2):571-7. PubMed ID: 1332703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
    Danks MK; Morton CL; Pawlik CA; Potter PM
    Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
    Masumoto N; Nakano S; Esaki T; Fujishima H; Tatsumoto T; Niho Y
    Int J Cancer; 1995 Jul; 62(1):70-5. PubMed ID: 7601570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
    Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolism of CPT-11. Impact on activity.
    Rivory LP
    Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.
    Guichard SM; Morton CL; Krull EJ; Stewart CF; Danks MK; Potter PM
    Clin Cancer Res; 1998 Dec; 4(12):3089-94. PubMed ID: 9865925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of SN-38 (an active metabolite of CPT-11) on responses of human and rodent cells to irradiation.
    Sasai K; Guo GZ; Shibuya K; Oya N; Shibata T; Nagata Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):785-8. PubMed ID: 9845096
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11.
    Onishi Y; Oguro M; Kizaki H
    Cancer Chemother Pharmacol; 1997; 39(6):473-8. PubMed ID: 9118457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
    Jones CB; Clements MK; Wasi S; Daoud SS
    Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
    McDonald AC; Brown R
    Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irinotecan (CPT-11): a brief overview.
    Rivory LP
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV-resonance Raman spectroscopy.
    Feofanov AV; Baranov AV; Fleury F; Riou JF; Nabiev IR; Manfait M
    FEBS Lett; 1996 Nov; 396(2-3):289-92. PubMed ID: 8915005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
    Chen TC; Su S; Fry D; Liebes L
    Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
    Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
    Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
    Kaneda N; Nagata H; Furuta T; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
    Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
    Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.